SLA2 Gene: Src Like Adaptor 2

Comprehensive genomic and functional analysis of SLA2, a key adaptor protein in immune signaling and cancer.

Gene Information Card

Symbol SLA2
Full Name Src Like Adaptor 2
Gene Type protein-coding
Chromosomal Location 20q11.23
NCBI Gene ID 84174 ncbi.nlm.nih.gov/gene/84174
Ensembl ID ENSG00000101204
UniProt ID Q9H6Q3
OMIM ID 609009
HGNC ID 20244
Aliases SLAP-2, SLAP2, MGC138207

Description

SLA2 (Src Like Adaptor 2) encodes a member of the Src-like adaptor protein (SLAP) family. This protein functions as an adaptor in intracellular signaling pathways, particularly in T-cell receptor (TCR) and B-cell receptor (BCR) signaling, where it negatively regulates immune responses by recruiting ubiquitin ligases to activated receptors. SLA2 is implicated in hematological malignancies and solid tumors through altered expression and mutations.

Disease Associations

Disease category Pathophysiological mechanism Genomic evidence
Chronic Lymphocytic Leukemia (CLL) Altered SLA2 expression may disrupt BCR signaling, contributing to leukemogenesis. ClinVar, COSMIC
Breast Cancer SLA2 mutations and copy number alterations affect cell proliferation pathways. COSMIC
Lung Cancer Somatic mutations in SLA2 are observed, potentially impacting immune evasion. COSMIC

Expression Profile

Tissue Expression
Tissue nTPM level
Spleen 12.5 Medium
Lymph node 10.8 Medium
Bone marrow 8.3 Low
Lung 5.1 Low
Breast 3.2 Low
Cell Line Expression
Cell Line nTPM Notes
K-562 (leukemia) 15.2 High expression
MCF7 (breast cancer) 4.7 Low expression
A549 (lung cancer) 6.1 Low expression
HEK293 (embryonic kidney) 2.3 Very low expression
Data source:Human Protein Atlas(proteinatlas.org)

Mutations & Variants

Hotspot Mutations
Variant Type Frequency Functional Description
p.Arg94Trp Missense <0.1% Unknown; predicted possibly damaging
p.Glu129* Nonsense <0.01 Loss of function
c.456+1G>A Splice site <0.01 Likely loss of function
Mutation functional classification

Loss of Function (LOF)

Nonsense and splice site mutations in SLA2 are predicted to cause loss of function, potentially impairing negative regulation of immune signaling.

Gain of Function (GOF)

No gain-of-function mutations have been reported for SLA2.

Dominant Negative (DN)

No dominant-negative mutations have been characterized for SLA2.

Pathways

• TCR signaling (Reactome: R-HSA-202403)
• BCR signaling (Reactome: R-HSA-983705)
• Immune System (Reactome: R-HSA-168256)

Protein Summary

SLA2 is a 261-amino acid adaptor protein containing an N-terminal SH3 domain and a C-terminal SH2 domain. It interacts with activated receptor tyrosine kinases and immune receptors, recruiting Cbl ubiquitin ligases to promote receptor downregulation. SLA2 is predominantly expressed in hematopoietic tissues and plays a critical role in modulating immune responses. Dysregulation of SLA2 is associated with lymphoid malignancies and solid tumors.

Related Products

Product name Cat.No. Species Gene ID
SLA2 Knockout HCT 116 Cell Line EDJ-KQ74465 Human 84174 Details Get a Quote
SLA2 Knockout A-549 Cell Line EDJ-KQ66041 Human 84174 Details Get a Quote
SLA2 Knockout HeLa Cell Line EDJ-KQ57543 Human 84174 Details Get a Quote
SLA2 Knockout HEK293 Cell Line EDJ-KQ10007 Human 84174 Details Get a Quote
Contact Us
*
*
*
How did you hear about us: